logo
FDA lays off bird flu leadership, among steep cuts to senior veterinarians

FDA lays off bird flu leadership, among steep cuts to senior veterinarians

CBS News02-04-2025

The top veterinarians overseeing the
bird flu response
at the Food and Drug Administration's Center for Veterinary Medicine were laid off on Tuesday, as part of
sweeping cuts
ordered by Health and Human Services Secretary Robert F. Kennedy Jr. to the nation's health agencies.
Out of some 10,000 workers laid off Tuesday across the Department of Health and Human Services, more than 130 staff were cut in the FDA's veterinary center, multiple officials said. The center oversees medicines and food given in the U.S. to animals, ranging from pets to cattle.
Officials said cuts impacted virtually all of the leadership team in the Center for Veterinary Medicine's office of the director, except for the director herself, Tracey Forfa.
Management and administrative teams were also gutted at CVM, including communications and purchasing staff, officials said, similar to other centers within the FDA.
"The food compliance officers and animal drug reviewers survived, but they have no one at the comms office to put out a safety alert, no admin staff to pay external labs to test products," one FDA official said, who was not authorized to speak publicly.
Two senior veterinarians in CVM had been overseeing its bird flu efforts, which was tasked with leading several aspects of the FDA's response to the virus, including investigating pet illness complaints and recalls.
Other work overseen by now-cut senior veterinarians at the agency included work on antimicrobial resistance and investigations into contaminated animal feed, which could end up contaminating meat or dairy products made from animals who consume tainted products.
News of the veterinarians' layoffs was previously reported by Reuters.
Several
multistate recalls of pet food
contaminated with the bird flu virus have been announced in recent months by the FDA and pet food manufacturers. While most humans have survived bird flu infections, the virus has been especially lethal to some animals like cats.
Veterinarians in the office had also been overseeing other efforts to curb bird flu, including standing up lab capacity to test pet products and research into gene editing chickens for resistance to the virus, as well as interest in better therapeutics for animals, an official said.
The FDA's chief medical officer, Dr. Hilary Marston, was also ousted Tuesday from the agency. She had been closely working to coordinate the agency's bird flu response with CVM's veterinarians, as well as to lead its oversight of human drugs and vaccines for the virus.
"I am sad that this chapter is coming to an end and very sorry for others experiencing the same," Marston, who also played a key role in the federal government's responses to the COVID-19 and mpox outbreaks, posted Tuesday
on LinkedIn
.
The FDA's Human Foods Program also lost more than 100 staff, including administrative and communications staff supporting scientists and health officials responding to the bird flu response alongside other teams, multiple officials said.
Other parts of the bird flu response may have also been affected as a result of Tuesday's cuts, officials said.
Staff in the U.S. Centers for Disease Control and Prevention's divisions investigating respiratory diseases and emerging infectious diseases were not among those cut at the Atlanta-based agency, according to unofficial lists circulated among CDC staff.
But more than 80 people were cut at the Administration for Strategic Preparedness and Response, two officials said.
ASPR, which is set to be merged into the CDC as part of Kennedy's restructuring, oversees funding of pandemic stockpiles of influenza vaccines and treatments.
Cuts at the agency affected ASPR's IT teams as well as the Biomedical Advanced Research and Development Authority, which funds research and production of vaccines and drugs, as well as workers for the Strategic National Stockpile, one official said.
Unlike Kennedy's HHS, the U.S. Department of Agriculture has not begun its White House-ordered "reduction in force" efforts, one official said, aside from offering early retirements and buyouts to many staff.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Dilon Technologies, Inc. Closes $9 Million in Growth Capital Financing
Dilon Technologies, Inc. Closes $9 Million in Growth Capital Financing

Yahoo

time37 minutes ago

  • Yahoo

Dilon Technologies, Inc. Closes $9 Million in Growth Capital Financing

NEWPORT NEWS, Va., June 9, 2025 /PRNewswire/ -- Dilon Technologies®, a global leader in medical devices for biosurgery and breast cancer treatment and diagnosis, today announced a $9 million growth capital investment from JGB Management Inc. The investment will support Dilon's continued double-digit revenue growth and operational scaling. Dilon Technologies has built a robust presence in surgical settings with a portfolio of products that improve clinical outcomes. "We are proud to partner with JGB as we advance our mission to deliver evidence-based surgical solutions worldwide," said George Makhoul, CEO of Dilon Technologies. "This funding empowers us to continue delivering best-in-class innovations that improve patient care." HEMOBLAST Bellows® is a groundbreaking advanced hemostatic agent used in a wide range of surgeries—including cardiac, general, and orthopedic procedures. It remains the only FDA-approved product specifically indicated for the control of minimal, mild, and moderate bleeding. Now utilized in several hundred U.S. hospitals, HEMOBLAST® Bellows continues to redefine standards in surgical hemostasis. Another key product, MarginProbe® an in-surgery, real-time breast cancer margin assessment device. It enables surgeons to assess lumpectomy margins intraoperatively, significantly reducing the need for repeat surgeries. Clinical studies show MarginProbe® reduces re-excision rates by 25% to 80%. A 2025 study published in The American Surgeon Journal highlighted a 42% reduction in re-excision for patients with DCIS. A next-generation version of the device has been submitted to the FDA, with approval anticipated by year-end. Dilon's Navigator™ Gamma Probe product line, a market-leading tool for radio-guided lymphatic mapping and tumor localization, continues to perform strongly worldwide. A new, enhanced version is expected to launch by late 2025. "We are pleased to partner with Dilon Technologies to help them grow in their mission to provide surgical solutions worldwide," said Brett Cohen, CEO of JGB Management Inc. For more information, visit About Dilon Technologies® Technologies® Inc. is a commercial-stage medical device company that develops, manufactures, and markets innovative technologies used in hemostasis, cancer detection and assessment, and airway management. Dilon's growing surgical portfolio includes: HEMOBLAST Bellows®: The only FDA-approved powder-form hemostatic agent for minimal, mild, and moderate bleeding. MarginProbe®: A groundbreaking real-time margin assessment tool for breast cancer surgery. Navigator™ System: A leading surgical gamma probe for tumor localization and lymphatic mapping. TrueView 100 Pro: A surgical specimen analyzer for intraoperative use. CoPilot VL+®: A compact, portable video laryngoscope for airway visualization. About JGB Management Inc. JGB Management Inc., founded by Brett Cohen in 2005, is an alternative asset management firm focused on investing in niche credit-oriented situations. JGB specializes in privately negotiated investments. The firm is based in Westport CT. View original content to download multimedia: SOURCE Dilon Technologies Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Aethlon Medical to Present New Pre-Clinical Data at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes
Aethlon Medical to Present New Pre-Clinical Data at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes

Yahoo

time37 minutes ago

  • Yahoo

Aethlon Medical to Present New Pre-Clinical Data at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes

Poster Presentation Reviews the Hemopurifier® Affinity Resin's Ability to Bind Extracellular Vesicles in Long COVID Samples SAN DIEGO, June 9, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that an abstract has been accepted for poster presentation at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes being held at Eldorado Hotel & Spa, Santa Fe, NM, United States, August 10-13,2025 ( Long COVID refers to persistent symptoms following acute SARs-CoV-2 infection (COVID-19). These symptoms - including fatigue, post-exertional malaise, shortness of breath, chest pain and cognitive difficulties such as "brain fog" - may last for weeks or months after the initial illness. Long COVID is estimated to affect between 44 and 48 million people in the United States alone with a projected economic burden of $2 billion for those with symptoms lasting a year. Despite over $1 billion allocated to Long COVID research funding, no treatment has proven effective. Extracellular vesicles (EVs), nanoparticles 50-500nm in diameter, released from all cell types and involved in cell-to-cell communication, have been implicated in the pathogenesis of Long COVID. EVs have been found to contain viral particles and other cargo associated with abnormal blood clotting and inflammation. Aethlon Medical's Hemopurifier® is an investigational extracorporeal device designed to bind and remove harmful EVs from the blood through a combination of plasma separation, size exclusion and binding to a proprietary affinity resin containing the plant lectin Galanthus nivalis agglutinin (GNA), previously found to bind to the sugar mannose. The Hemopurifier has previously been shown to remove EVs in a patient with severe acute COVID-19 infection. Aethlon Medical collaborated with the University of California San Francisco Medical Center Long COVID clinic to evaluate plasma samples from participants with Long COVID and control participants who had fully recovered from COVID-19 in order to examine whether individuals with Long COVID would have EVs with the mannose target on their surface that would bind to the affinity resin in the device. The data to be presented will review the binding of both larger and smaller EVs to GNA lectin and the lectin-based affinity resin, respectively. Presentation details and times are as follows: Title: Extracellular Vesicles from Participants with Long COVID are Mannosylated and Bind to the Galanthus Nivalis Agglutinin Resin in the Aethlon Hemopurifier® Authors: Miguel Pesqueira1, Rosalia de Necochea Campion1, Thomas Dalhuisen2, Emily A. Fehrman2, Jeffrey N. Martin2, Timothy J. Henrich2, Steven G. Deeks2, Michael J. Peluso2, Steven P. LaRosa1 Aethlon Medical Inc., San Diego, CA, USA University of California, San Francisco, San Francisco, CA, USA Presenter: Steven P. LaRosa, M.D, Chief Medical Officer, Aethlon Medical, Number: 2001Date and Time: August 12, 2025, 1930, MDT. This poster will be available following the meeting on the Aethlon Medical, Inc. corporate website at About Aethlon and the Hemopurifier® Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful EVs from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where EVs may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which EVs have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation, and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies. Additional information can be found at Company Contact:Jim FrakesChief Executive Officer and Chief Financial OfficerAethlon Medical, Inc. Jfrakes@ Investor Contact:Susan NoonanS.A. Noonan Communications, LLCsusan@ View original content: SOURCE Aethlon Medical, Inc. Sign in to access your portfolio

TYBR Health Announces FDA 510(k) Clearance for B3 GEL™ System, a Flowable Bio-Gel to Protect Healing Tissue and Preserve Function
TYBR Health Announces FDA 510(k) Clearance for B3 GEL™ System, a Flowable Bio-Gel to Protect Healing Tissue and Preserve Function

Yahoo

time37 minutes ago

  • Yahoo

TYBR Health Announces FDA 510(k) Clearance for B3 GEL™ System, a Flowable Bio-Gel to Protect Healing Tissue and Preserve Function

HOUSTON, June 9, 2025 /PRNewswire/ -- TYBR Health, a medical device and regenerative medicine company, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the B3 GEL™ System. B3 GEL™ is a bioresorbable, flowable gel barrier designed to protect healing tissue planes and preserve mobility following surgeries involving tendons, ligaments, and skeletal muscle. This clearance marks a significant milestone for TYBR Health, enabling a new approach to support functional recovery in musculoskeletal surgery. B3 GEL™ helps maintain surgical precision by temporarily separating tissues during the early healing phase—without impeding the natural healing process. "When we started TYBR, it was with a clear purpose: to solve a real, overlooked problem in surgical recovery," said Tim Keane, PhD, Cofounder and CEO of TYBR Health. "Too often, healing goes unprotected once the procedure ends. B3 GEL™ is designed to fill that gap—working with the body's biology to protect tissue planes and give surgeons a way to safeguard patient outcomes during the critical early phase of recovery." B3 GEL™ is composed of a naturally derived extracellular matrix and is applied via TYBR's proprietary integrated mixer-applicator system. Its flowable format conforms to complex anatomy and can be used in both open and minimally invasive procedures. The blue-colored gel allows for visual confirmation of placement and resorbs completely over time without leaving residual bulk. Preclinical studies submitted to support clearance demonstrated that B3 GEL™ reduced tissue binding and supported improved range of motion in treated models, with enhanced flexion and extension compared to controls (data on file). TYBR Health plans to begin commercial sales of the B3 GEL™ System by the end of 2025. About TYBR HealthFounded in 2020, TYBR Health is a medical device and regenerative medicine company focused on improving surgical recovery. Headquartered in Houston, Texas, TYBR develops solutions that help surgeons protect healing tissues and preserve function after surgery. Its lead product, the B3 GEL™ System, is a bioresorbable gel barrier cleared by the FDA to aid in the protection of soft tissues during post-surgical healing. TYBR is targeting a significant unmet need in musculoskeletal surgery, where recovery complications impact function and healthcare costs. With FDA clearance secured, manufacturing in place, and a proprietary delivery system developed for precise, intraoperative use, TYBR is preparing for commercial launch in late 2025. For more information contact: info@ View original content to download multimedia: SOURCE TYBR Health

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store